Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 14 | 1 |
| List of Figures | 14 | 1 |
| Takeda Pharmaceutical Company Limited Snapshot | 15 | 1 |
| Takeda Pharmaceutical Company Limited Overview | 15 | 1 |
| Key Information | 15 | 1 |
| Key Facts | 15 | 1 |
| Takeda Pharmaceutical Company Limited Research and Development Overview | 16 | 7 |
| Key Therapeutic Areas | 16 | 7 |
| Takeda Pharmaceutical Company Limited Pipeline Review | 23 | 7 |
| Pipeline Products by Stage of Development | 23 | 1 |
| Pipeline Products Monotherapy | 24 | 1 |
| Pipeline Products Combination Treatment Modalities | 25 | 1 |
| Pipeline Products Partnered Products | 26 | 1 |
| Partnered Products/Combination Treatment Modalities | 27 | 1 |
| Pipeline Products Out-Licensed Products | 28 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 29 | 1 |
| Takeda Pharmaceutical Company Limited Pipeline Products Glance | 30 | 11 |
| Takeda Pharmaceutical Company Limited Late Stage Pipeline Products | 30 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 30 | 1 |
| Filing rejected/Withdrawn Products/Combination Treatment Modalities | 31 | 1 |
| Phase III Products/Combination Treatment Modalities | 32 | 1 |
| Takeda Pharmaceutical Company Limited Clinical Stage Pipeline Products | 33 | 1 |
| Phase II Products/Combination Treatment Modalities | 33 | 1 |
| Phase I Products/Combination Treatment Modalities | 34 | 1 |
| Phase 0 Products/Combination Treatment Modalities | 35 | 1 |
| Takeda Pharmaceutical Company Limited Early Stage Pipeline Products | 36 | 1 |
| IND/CTA Filed Products/Combination Treatment Modalities | 36 | 1 |
| Preclinical Products/Combination Treatment Modalities | 37 | 3 |
| Discovery Products/Combination Treatment Modalities | 40 | 1 |
| Takeda Pharmaceutical Company Limited Drug Profiles | 41 | 133 |
| (alogliptin benzoate + metformin hydrochloride) | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 2 |
| (alogliptin benzoate + pioglitazone hydrochloride) | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 3 |
| brentuximab vedotin | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 7 |
| ceftaroline fosamil | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 3 |
| ixazomib citrate | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 5 |
| ramelteon | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 2 |
| vedolizumab | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 2 |
| roflumilast | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 5 |
| (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| azilsartan medoxomil | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 2 |
| febuxostat XR | 73 | 1 |
| Product Description | 73 | 1 |
| Mechanism of Action | 73 | 1 |
| R&D Progress | 73 | 1 |
| immune globulin (human) | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 2 |
| pioglitazone hydrochloride | 76 | 1 |
| Product Description | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| R&D Progress | 76 | 2 |
| rasagiline mesylate | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 1 |
| relugolix | 79 | 1 |
| Product Description | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| R&D Progress | 79 | 1 |
| TAK-003 | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 3 |
| vortioxetine hydrobromide | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 3 |
| AM-4 | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| DSM-265 | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 2 |
| namilumab | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| R&D Progress | 89 | 2 |
| TAK-063 | 91 | 1 |
| Product Description | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| R&D Progress | 91 | 2 |
| TAK-214 | 93 | 1 |
| Product Description | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| R&D Progress | 93 | 2 |
| TAK-272 | 95 | 1 |
| Product Description | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| R&D Progress | 95 | 1 |
| TAK-850 | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| R&D Progress | 96 | 2 |
| J-591 | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 1 |
| TAK-020 | 99 | 1 |
| Product Description | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| R&D Progress | 99 | 1 |
| TAK-021 | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| TAK-058 | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 1 |
| TAK-071 | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| TAK-079 | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| TAK-653 | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| TAK-792 | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 1 |
| TAK-828 | 106 | 1 |
| Product Description | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| R&D Progress | 106 | 1 |
| TAK-831 | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 1 |
| TAK-915 | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| R&D Progress | 108 | 1 |
| TAK-935 | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 1 |
| trelagliptin succinate | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 2 |
| (plague + small pox) vaccine | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 1 |
| BTZO-2 | 113 | 1 |
| Product Description | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| R&D Progress | 113 | 1 |
| chikungunya vaccine | 114 | 1 |
| Product Description | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| R&D Progress | 114 | 1 |
| ELQ-300 | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 1 |
| influenza [strain A/H5N1] vaccine | 116 | 1 |
| Product Description | 116 | 1 |
| Mechanism of Action | 116 | 1 |
| R&D Progress | 116 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine | 117 | 1 |
| Product Description | 117 | 1 |
| Mechanism of Action | 117 | 1 |
| R&D Progress | 117 | 1 |
| mapatumumab | 118 | 1 |
| Product Description | 118 | 1 |
| Mechanism of Action | 118 | 1 |
| R&D Progress | 118 | 2 |
| Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer | 120 | 1 |
| Product Description | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| R&D Progress | 120 | 1 |
| Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| R&D Progress | 121 | 1 |
| Monoclonal Antibody Conjugates for Oncology | 122 | 1 |
| Product Description | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| R&D Progress | 122 | 1 |
| respiratory syncytial virus (virus like particle) vaccine | 123 | 1 |
| Product Description | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| R&D Progress | 123 | 1 |
| Rotavirus (virus like particle) vaccine | 124 | 1 |
| Product Description | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| R&D Progress | 124 | 1 |
| Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression | 125 | 1 |
| Product Description | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| R&D Progress | 125 | 1 |
| Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease | 126 | 1 |
| Product Description | 126 | 1 |
| Mechanism of Action | 126 | 1 |
| R&D Progress | 126 | 1 |
| Small Molecule to Activate Glucokinase for Type 2 Diabetes | 127 | 1 |
| Product Description | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| R&D Progress | 127 | 1 |
| Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain | 128 | 1 |
| Product Description | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| R&D Progress | 128 | 1 |
| Small Molecule to Agonize GPR52 for Psychiatry Disorders | 129 | 1 |
| Product Description | 129 | 1 |
| Mechanism of Action | 129 | 1 |
| R&D Progress | 129 | 1 |
| Small Molecule to Antagonize Androgen Receptor for Prostate Cancer | 130 | 1 |
| Product Description | 130 | 1 |
| Mechanism of Action | 130 | 1 |